Progenics Pharmaceuticals , Inc.


777 Old Saw Mill River RdTarrytownNew York10591United States View Map


$8.7 Million



SIC Codes:

2834, 3721

NAICS Codes:

325412, 541711


(914) 789-2800


(914) 789-2817


Progenics Pharmaceuticals, Inc. is developing innovative medicines and other products for targeting and treating cancer, with a pipeline that includes several product candidates in later-stage clinical development. These products in development include therapeutic agents designed to precisely target cancer (AZEDRA®, 1095 and PSMA ADC), and PSMA-targeted imaging agents for prostate cancer (1404 and PyL) intended to enable clinicians and patients to accurately visualize and manage their disease. In addition, in late 2015 Progenics acquired EXINI Diagnostics AB, a leader in the development of advanced artificial intelligence-based imaging analysis tools and solutions for medical decision support. The acquisition of EXINI complements Progenics' strategy to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help physicians and patients visualize, understand, target and treat cancer. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Valeant Pharmaceuticals International, Inc.

Read More


Recently Updated profiles at this company

Associate Director of Human Resources

Vice President of Commercial

Clinical Project Manager

Vice President of Clinical Affairs

Senior Manager of Investor Relations

Vice President of Clinical Development


Position, Pharmaceutical Industry

Senior Manager, Clinical Data Management

Senior Vice President and Chief Financial Officer

Browse ZoomInfo’s Directories